



## Company profile

Microba is a microbial genomics company based at the Princess Alexandra Hospital Campus in Brisbane. It specialises in gut microbiome sequencing using world-leading technology paired with expert data analysis. We provide services to individuals, healthcare professionals, clinical trials and researchers to investigate the gut microbiome and its links with health and disease. Taking a big data approach, we also combine our analysis potential with targeted investigations to create future diagnostics and therapeutics.

The gut microbiome is the next frontier in science and medicine. It has been labelled as an organ by many due to the essential role it is playing in food digestion, pathogen resistance, drug efficacy, immune homeostasis and vitamin production. This group of microorganisms is the subject of interest for many leading pharma companies, biotech companies and clinicians around the world.

Microba's Metagenomic Analysis Platform (MAP) technology delivers a market leading solution for analysing the Gut Microbiome. Most other platforms use 16S rRNA testing, which only sequences a small part of a single bacterial gene. Microba uses metagenomics, which sequences all the genes from the microorganisms in a sample and can provide much higher-resolution information.

Microba has launched the Microba Insight™ product which is the only test in Australia that provides consumers with the whole picture of their gut microbiome. While other services use 16S rRNA testing, which can only detect groups of bacteria, Microba uses metagenomics, which provides species level resolution of bacteria, archaea, and key fungi and protists, as well as information on the potential functions of the microorganisms.

Due to the capability of the Microba platform to measure pathogens and anti-microbial resistance genes, it is also being assessed as a pathology screening tool. The measurement of the entire microbial community and functional genes will provide distinct benefits to clinicians, patients and payers.

By undertaking deep genomic analysis of the gut microbiome and applying AI and machine learning approaches to this rich data set Microba is well positioned to identify new therapeutic candidates and biomarkers which are validated for pre-clinical programs. This approach is enabling the rapid development of live biotherapeutic candidates and screening tools.



### Speaker Profile

Mr Wills is an entrepreneur who has worked in the life sciences, finance and education sectors. During these roles he has launched and acquired multiple businesses in Australia and internationally. As CEO of Microba, Mr Wills has made world leading technology available to Australian consumers providing them with significant new insight into their gut microbiome. Bringing science to life and developing real world applications for technology is a passion for Mr Wills.

